BostonGene, developer of the leading AI foundation model for cancer and the immune system, and Kyoto University, a research institution known for its groundbreaking advancements in medicine and science, announced today a research collaboration to develop advanced biological signatures to enhance targeted treatment strategies for patients with esophageal squamous cell carcinoma (ESCC)..

波士顿基因公司（BostonGene）是领先的癌症和免疫系统人工智能基础模型开发者，京都大学则是以其在医学和科学领域的开创性进展而闻名的研究机构，双方今天宣布了一项研究合作，旨在开发先进的生物标志物，以优化食管鳞状细胞癌（ESCC）患者的靶向治疗策略。

This research will leverage BostonGene’s AI-powered, multi-scale, omnimodal platform to analyze tumor molecular profiles and assess their correlation with response to a novel immune checkpoint inhibitor (ICI) and chemoradiotherapy (CRT) combination therapy. The study builds on the NOBEL trial, an investigator-initiated clinical study led by Dr.

这项研究将利用BostonGene的AI驱动、多尺度、全模态平台，分析肿瘤分子特征，并评估其与新型免疫检查点抑制剂（ICI）和放化疗（CRT）联合治疗反应的相关性。该研究基于NOBEL试验，这是一项由博士领导的研究者发起的临床研究。

Manabu Muto of Kyoto University, by integrating genomic and transcriptomic profiling from ESCC patients to identify immune-related biomarkers that drive drug development, optimize clinical trial design and enable more accurate patient stratification..

京都大学的武藤学通过整合食管鳞状细胞癌（ESCC）患者的基因组和转录组分析，识别推动药物开发、优化临床试验设计并实现更精确患者分层的免疫相关生物标志物。

As part of the collaboration, Kyoto University will provide clinical samples and patient data and BostonGene will apply its AI-powered molecular analytics to uncover key biological pathways and associated biomarkers influencing treatment response.

作为合作的一部分，京都大学将提供临床样本和患者数据，波士顿基因公司将利用其人工智能驱动的分子分析技术，揭示影响治疗反应的关键生物通路和相关生物标志物。

'This collaboration will generate actionable insights into the tumor microenvironment and immune landscape of esophageal cancer,' said Yukimasa Shiotsu, PhD, President of BostonGene Japan. 'Combining Kyoto University’s clinical expertise and BostonGene’s AI-powered analytics, we will refine and advance precision treatment strategies for ESCC patients.'.

“这次合作将生成关于食道癌肿瘤微环境和免疫景观的可操作见解，”波士顿基因日本总裁盐津幸正博士说道。“结合京都大学的临床专业知识和波士顿基因的AI驱动分析，我们将完善并推进针对食管鳞状细胞癌患者的精准治疗策略。”

'Understanding the molecular and immune characteristics of ESCC is essential for developing more effective treatment strategies,' said Dr. Manabu Muto, Professor at Kyoto University and Principal Investigator of the NOBEL trial. 'Through this collaboration, we will apply cutting-edge AI-powered analytics to clinical data, enabling us to identify biomarkers that can directly inform treatment decisions and improve patient outcomes.'.

“了解食管鳞状细胞癌（ESCC）的分子和免疫特征，对于制定更有效的治疗策略至关重要，”京都大学教授、NOBEL试验首席研究员武藤学博士表示。“通过此次合作，我们将把尖端的人工智能分析技术应用于临床数据，从而识别能够直接指导治疗决策并改善患者预后的生物标志物。”

About BostonGene Corporation

关于波士顿基因公司

BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights.

BostonGene通过整合多模态数据和人工智能，正在重新定义癌症患者的护理和药物开发。BostonGene的癌症与免疫系统基础模型依托广泛的现实世界临床测试网络构建和验证，该模型整合了基因组、转录组和免疫数据以及临床结果，生成基于生物学的、可操作的见解。

These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation. For more information, visit www.BostonGene.com..

这些见解使生物制药合作伙伴能够设计和降低试验风险、确定新的靶点，并在开发的所有阶段优化治疗反应预测，同时通过临床集成创新改善患者护理。欲了解更多信息，请访问 www.BostonGene.com。

About NOBEL trial

关于诺贝尔试验

NOBEL trial is a Phase II study evaluating the efficacy and safety of a combination treatment of chemoradiotherapy and an immune checkpoint inhibitor for advanced esophageal cancer.

NOBEL试验是一项II期研究，评估化疗放疗联合免疫检查点抑制剂治疗晚期食管癌的疗效和安全性。

The NOBEL trial is being conducted as an investigator-initiated trial with financial support from Ono Pharmaceutical Co., Ltd.

NOBEL 试验作为研究者发起的试验进行，得到了小野药品工业株式会社的财务支持。

About BostonGene Japan

关于波士顿基因日本

BostonGene Japan Inc., a Tokyo-based joint venture formed by BostonGene, NEC Corporation and Japan Industrial Partners aims to advance personalized medicine and dramatically improve patient outcomes. The company leverages BostonGene’s AI-powered multiomics platform to accelerate drug development and personalize cancer therapies for each patient..

总部位于东京的波士顿基因日本公司（BostonGene Japan Inc.）是由波士顿基因、日本电气公司（NEC Corporation）和日本产业伙伴（Japan Industrial Partners）共同成立的合资企业，旨在推动个性化医疗并显著改善患者预后。该公司利用波士顿基因的AI驱动多组学平台，加速药物开发，并为每位患者个性化定制癌症治疗方案。

About Kyoto University

关于京都大学

Kyoto University states its mission to sustain and develop its historical commitment to academic freedom and to pursue harmonious coexistence within the human and ecological community on this planet. For more information, visit https://www.kyoto-u.ac.jp/en/about/profile/ideals

京都大学的使命是坚持和发扬其对学术自由的历史承诺，并追求人类与地球生态社区的和谐共存。欲了解更多信息，请访问 https://www.kyoto-u.ac.jp/en/about/profile/ideals

Source: bostongene.com

来源：bostongene.com